AstraZeneca’s Asthma drug Benralizumab gets marketing approval from DCGI
Benralizumab is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Gagandeep Singh Bedi
AstraZeneca India receives marketing permission for QTERN
Once-daily anti-diabetes treatment for adults with type-2 diabetes, QTERN combines two anti-hyperglycaemic agents with…